^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Telomerase inhibitor

    Related drugs:
    2d
    NRG-GI007: Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, NRG Oncology | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    carboplatin • paclitaxel • Telomelysin (suratadenoturev)
    3d
    A prospective, single-center, single-arm study to evaluate the efficacy and safety of imetelstat in adults with severe alopecia areata refractory to systemic therapy. (ChiCTR2600117015)
    P=N/A, N=32, Not yet recruiting, Affiliated Hospital of Guilin Medical University; Affiliated Hospital of Guilin Medical University
    New trial
    |
    imatinib • Rytelo (imetelstat)
    5d
    Solid dispersion of BIBR1532: A potent therapeutic for oesophageal squamous cancer. (PubMed, World J Gastrointest Oncol)
    HPMC-based SD enhances BIBR1532 solubility and bioavailability for effective ESCC treatment. Future studies should focus on pilot tests for SD fabrication.
    Journal
    |
    CHEK2 (Checkpoint kinase 2) • CHEK1 (Checkpoint kinase 1)
    |
    BIBR1532
    13d
    THIO-101: THIO Sequenced With Cemiplimab in Advanced NSCLC (clinicaltrials.gov)
    P2, N=227, Recruiting, Maia Biotechnology | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Sep 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Libtayo (cemiplimab-rwlc) • ateganosine (THIO)
    22d
    THIO-104: A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC (clinicaltrials.gov)
    P3, N=300, Recruiting, Maia Biotechnology | Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
    |
    gemcitabine • docetaxel • Libtayo (cemiplimab-rwlc) • vinorelbine tartrate • ateganosine (THIO)
    22d
    Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat. (PubMed, Leukemia)
    Lastly, 60% of patients with ≥1-year RBC-TI had ≥50% reduction in telomerase activity/human telomerase reverse transcriptase RNA. These results suggest that imetelstat targets clonal progenitor cells and may modify LR-MDS biology.
    Journal
    |
    DNMT3A (DNA methyltransferase 1) • TERT (Telomerase Reverse Transcriptase) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    Rytelo (imetelstat)
    1m
    P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors. (PubMed, Anticancer Res)
    Our results suggest that P53-armed OBP-702 is a promising agent for improving the antitumor effect of PD1 blockade in treating invasive OS.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    PD-L1 expression
    |
    Telomelysin (suratadenoturev) • pfifteloxin (OBP-702)
    1m
    All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Dwight Owen | Trial primary completion date: Jan 2026 --> Sep 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Tecentriq (atezolizumab) • Vesanoid (tretinoin)
    1m
    Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (clinicaltrials.gov)
    P2, N=76, Terminated, Mario Negri Institute for Pharmacological Research | N=112 --> 76 | Trial completion date: Sep 2024 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Jan 2025; Low enrolment rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    anastrozole • Vesanoid (tretinoin)
    2ms
    Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P2, N=151, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
    |
    Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide
    2ms
    Updates in low/intermediate-risk MDS. (PubMed, Hematology Am Soc Hematol Educ Program)
    New therapeutic options to reduce the red blood cell (RBC) transfusion burden have emerged since 2020 and include luspatercept and imetelstat. Erythropoiesis-stimulating agents and lenalidomide also address anemia and are generally recommended to start at the time of transfusion dependency, although emerging data suggest that an earlier start of these interventions might offer clinical benefits...Targeted therapy directed to the presence of an IDH1 mutation is U.S. Food and Drug Administration (FDA) approved for the rare IDH1 mutated MDS (<10% of the time) and consideration to use an IDH2 inhibitor for IDH2 mutated MDS (<5% of the time) is reasonable. Interestingly, IDH mutations seem to appear with increased frequency in older patients and in patients with underlying autoimmune/rheumatological disorders.1.
    Review • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH2 mutation
    |
    lenalidomide • Reblozyl (luspatercept-aamt) • Rytelo (imetelstat)
    2ms
    Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 (clinicaltrials.gov)
    P2, N=67, Completed, GemVax & Kael | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    LucaVax (tertomotide)